论文部分内容阅读
对冠心病患者服用阿斯匹林（ＡＳＡ）前后的血小板α－颗粒膜蛋白１４０（ＧＭＰ－１４０）水平和血小板聚集率进行了测定。结果显示：冠心病患者治疗前血小板ＧＭＰ－１４０水平和聚集率显著高于正常人（Ｐ＜０．００１）。使用阿斯匹林（ＡＳＡ）治疗后两种指标明显下降（Ｐ＜０．００１），达到正常人水平（Ｐ＞０．０５）。提示ＡＳＡ能直接降低ＧＭＰ－１４０水平，抑制血小板活化和聚集，有效地防止冠状血管的进一步损害。
The levels of platelet α-granule membrane protein 140 (GMP-140) and platelet aggregation in patients with coronary heart disease before and after taking aspirin (ASA) were measured. The results showed that the level of GMP-140 and the aggregation rate of platelet in patients with coronary heart disease before treatment were significantly higher than those in normal people (P <0.001). After treatment with aspirin (ASA), the two indexes decreased significantly (P <0.001), reaching the normal level (P> 0.05). These results suggest that ASA can directly reduce the level of GMP-140, inhibit platelet activation and aggregation, and effectively prevent further damage to coronary vessels.